Product information
| Price | €175, €275, €395 |
|---|---|
| Size | 20 µl/µg | 50 µl/µg | 100 µl/µg |
| Short name | RNase Z2 Antibody |
| Host | Rabbit |
| Isotype | IgG |
| Target protein | ELAC2 |
| Recommended applications | ELISA, IHC-p |
| Reactivity | Human |
| Immunogen | The antiserum was produced against synthesized peptide derived from human ELAC2. AA range:161-210 |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Formulation | Liquid in PBS containing 50% glycerol; 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Product code | MB-AP14300 |
Additional information
Prev
Next
The protein encoded by ELAC2 (elaC ribonuclease Z 2) has a C-terminal domain with tRNA processing endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in ELAC2 result in an increased risk of prostate cancer. Multiple transcript variants encoding different isoforms have been found for ELAC2.
ELAC2, HPC2, Zinc phosphodiesterase ELAC protein 2, ElaC homolog protein 2, Heredity prostate cancer protein 2, Ribonuclease Z 2, RNase Z 2, tRNA 3 endonuclease 2, tRNase Z 2
Human: Q9BQ52, Mouse: Q80Y81
Human: 60528
